June 2011. Volume 7. Number 2

Indomethacin versus ibuprofen for closure of patent ductus arteriosus: the question is not about effectiveness, it's about safety

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Jones LJ, Craven PD, Attia J, Thakkinstian A, Wright I. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2011;96:F45-52.
Reviewers: de Armas Iglesias I1, González de Dios J2, Aparicio Sánchez JL3.
1Servicio de Pediatría.Hospital Dr. José Molina Orosa. Lanzarote. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
3Servicio de Pediatría. Hospital General de Lanzarote. Gran Canaria. España.
Correspondence: Idaira de Armas Iglesias. Email: idairadearmas@hotmail.com
Reception date: 27/04/2011
Acceptance date: 05/05/2011
Publication date: 11/05/2011

Abstract

Authors’ conclusion: intravenous indomethacin or ibuprofen administered to preterm infants older than 24 hours induced ductal closure, but other short-term benefits were not seen. Treatment with ibuprofen may increase the risk of chronic lung disease.

Reviewers’ commentary: both drugs are effective for patent ductus arteriosus closure. The choice between them will depend on safety criteria. We should take into account that the risk of chronic lung disease seems to be higher with ibuprofen, and oliguria is more frequent in patients treated with indomethacin.

How to cite this article

de Armas Iglesias I, González de Dios J, Aparicio Sánchez JL. Indometacina e ibuprofeno en el tratamiento del conducto arterial persistente del prematuro: la duda no es la eficacia, sino la seguridad. Evid Pediatr. 2011;7:45.

AVC | Critically appraised articles

Jones LJ, Craven PD, Attia J, Thakkinstian A, Wright I. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2011;96:F45-52.
Reviewers: de Armas Iglesias I1, González de Dios J2, Aparicio Sánchez JL3.
1Servicio de Pediatría.Hospital Dr. José Molina Orosa. Lanzarote. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
3Servicio de Pediatría. Hospital General de Lanzarote. Gran Canaria. España.
Correspondence: Idaira de Armas Iglesias. Email: idairadearmas@hotmail.com
Reception date: 27/04/2011
Acceptance date: 05/05/2011
Publication date: 11/05/2011

How to cite this article

de Armas Iglesias I, González de Dios J, Aparicio Sánchez JL. Indometacina e ibuprofeno en el tratamiento del conducto arterial persistente del prematuro: la duda no es la eficacia, sino la seguridad. Evid Pediatr. 2011;7:45.

References

  1. Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R et al. Variations in practice and outcomes in the Canadian NICU Network 1996-1997. Pediatrics. 2000;106:1070-9.
  2. Ohlsson A, Walia R, Shah SS. Ibuprofen fort the treatment of patent ductusarteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2010;14:CD003481.
  3. Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr. 2005;164:135-40.
  4. Gimeno Navarro A, Modesto Alapont V, Morcillo Sopena F, Fernández Gilino C, Izquierdo Macián I, Gutiérrez Laso A. Ibuprofeno frente a indometacina para el tratamiento del conducto arterioso del prematuro: revisión sistémica y metaanálisis. An Pediatr (Barc). 2007;67:309-18.
  5. Gokmen T, Erdeve O, Altung N, Oguz SS, Dilmen U. Efficacy and safety of oral versus intravenous Ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr. 2011;158:549-54.
  6. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313-24.
11/05/2011

Linked Comment